← Back to Search

Personalized Information for Skin Cancer

N/A
Waitlist Available
Led By Peter Kanetsky, Ph.D
Research Sponsored by H. Lee Moffitt Cancer Center and Research Institute
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 12 month
Awards & highlights

Study Summary

This trial will test how well different messages about melanoma risk work to get people to change their behavior to reduce their risk.

Eligible Conditions
  • Skin Cancer
  • Squamous Cell Carcinoma
  • Squamous Cell Cancer
  • Basal Cell Carcinoma

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~12 month
This trial's timeline: 3 weeks for screening, Varies for treatment, and 12 month for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Outdoor Intentional Tanning - Hispanic Population - After Intervention
Outdoor Intentional Tanning - Hispanic Population - Baseline
Outdoor Intentional Tanning - NHW - After Intervention
+37 more
Secondary outcome measures
Outdoor Intentional Tanning - Hispanic Children Population - After Intervention
Outdoor Intentional Tanning - Hispanic Children Population - Baseline
Outdoor Intentional Tanning - NHW Children - After Intervention
+43 more

Trial Design

4Treatment groups
Experimental Treatment
Placebo Group
Group I: Intervention Group BExperimental Treatment2 Interventions
Intervention Group B: Hispanic Population Post determination of MC1R Genotypes, participants randomized to the intervention group, will receive personalized information about ways that they can protect themselves and their child from developing melanoma. By the end of the study, all participants will have had the opportunity to receive information about their inherited risk.
Group II: Intervention Group AExperimental Treatment2 Interventions
Intervention Group A: Non-Hispanic White Population Post determination of MC1R Genotypes, participants randomized to the intervention group, will receive personalized information about ways that they can protect themselves and their child from developing melanoma. By the end of the study, all participants will have had the opportunity to receive information about their inherited risk.
Group III: Control Group APlacebo Group2 Interventions
Control Group A: Non-Hispanic White Population Post determination of MC1R Genotypes, participants randomized to the control group, you will receive standard information about ways that they can protect themselves and their child from developing melanoma. By the end of the study, all participants will have had the opportunity to receive information about their inherited risk. Participants randomized into the control group, by the end of the study will also have had the opportunity to receive personalized information about ways they can protect themselves and their child from developing melanoma.
Group IV: Control Group BPlacebo Group2 Interventions
Control Group B: Hispanic Population Post determination of MC1R Genotypes, participants randomized to the control group, you will receive standard information about ways that they can protect themselves and their child from developing melanoma. By the end of the study, all participants will have had the opportunity to receive information about their inherited risk. Participants randomized into the control group, by the end of the study will also have had the opportunity to receive personalized information about ways they can protect themselves and their child from developing melanoma.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Personalized Information
2015
N/A
~2060

Find a Location

Who is running the clinical trial?

American Cancer Society, Inc.OTHER
224 Previous Clinical Trials
108,401 Total Patients Enrolled
The Ponce Health Sciences UniversityUNKNOWN
University of South FloridaOTHER
410 Previous Clinical Trials
184,854 Total Patients Enrolled

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
Recent research and studies
mc1rJournal
Assessment of Melanoma Precision Prevention Materials Incorporating <i>mc1r</i> Genetic Risk Information
Lacson, John Charles A, Stephanie M Forgas, Scarlet H Doyle, Lu Qian, Jocelyn Del Rio, Stella Valavanis, Rodrigo Carvajal, et al.. 2022. “Assessment of Melanoma Precision Prevention Materials Incorporating mc1r Genetic Risk Information”. Translational Behavioral Medicine. Oxford University Press (OUP). doi:10.1093/tbm/ibac034.
clinicaltrials.govStudy
Using MC1R Genotype to Impact Melanoma Risk Behavior
2015. "Using MC1R Genotype to Impact Melanoma Risk Behavior". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT03509467.
~212 spots leftby Apr 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top